Xeris Pharmaceuticals (XERS) AI Stock Analysis

• Market Cap: $1.59B
• Dividend Yield: N/A
• Average Volume (3M): 2.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.12
• Revenue Growth: 42.05%
• EPS Growth: 76.50%
• Country: US
• Employees: 394
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 161,480,360
• 10 Day Avg. Volume: 2,116,415
• 30 Day Avg. Volume: 2,197,287
• PEG Ratio: 0.51
• Price to Book (P/B): -16.80
• Price to Sales (P/S): 2.45
• P/FCF Ratio: -13.15
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $12.33
• Price Target Upside: 35.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $7.50 ▼(-17.40% Downside)

Xeris Pharmaceuticals' overall stock score is driven by its strong earnings call performance, which highlights record revenue growth and strategic plans for future growth. However, significant challenges in financial stability, profitability, and bearish technical indicators weigh heavily on the score.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful product adoption and market expansion, providing a solid foundation for future earnings.

Product Performance

RECORLEV's substantial revenue growth underscores its market acceptance and potential as a key revenue driver, enhancing long-term business prospects.

Cash Flow and Profitability

Achieving positive cash flow and net income marks a critical milestone, improving financial stability and supporting future investments.

Negative Factors

Financial Leverage

High financial leverage poses risks to financial stability, potentially limiting flexibility and increasing vulnerability to market fluctuations.

Profitability Challenges

Ongoing profitability challenges highlight operational inefficiencies, which could hinder long-term growth and shareholder value.

Increased Expenses

Rising expenses, particularly in R&D, could pressure margins and require careful management to ensure sustainable growth.

Xeris Pharmaceuticals Business Overview & Revenue Model

Company Description

Xeris Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for the treatment of chronic and acute diseases. The company primarily operates in the pharmaceutical sector, specializing in formulation technologies that allow for the delivery of biologics and other complex drugs. Xeris is known for its proprietary formulations of injectable medications, including its flagship product, XeriJect, which aims to enhance the convenience and efficacy of drug delivery for patients with diabetes and other conditions.

How the Company Makes Money

Xeris Pharmaceuticals generates revenue primarily through the commercialization of its proprietary products, such as XeriJect and other formulations in its pipeline. The company's revenue model includes sales of these products to healthcare providers and patients, as well as potential licensing agreements with larger pharmaceutical companies. Additionally, Xeris may benefit from partnerships that provide upfront payments, milestone payments, and royalties based on sales of partnered products. The company’s focus on innovative delivery systems positions it to capture market share in the growing injectable drug market, thereby contributing to its overall earnings.

Xeris Pharmaceuticals Financial Statement Overview

Summary

Xeris Pharmaceuticals is experiencing revenue growth but faces significant challenges in profitability and financial stability. The high leverage and negative equity position pose risks, while cash flow management remains a critical area for improvement.

Income Statement

Xeris Pharmaceuticals shows a positive revenue growth rate of 8.18% in the TTM, indicating a growing top line. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -13.01% and a negative EBIT margin. The gross profit margin remains strong at 81.14%, but the company needs to address its operational inefficiencies to improve overall profitability.

Balance Sheet

The balance sheet reveals significant financial leverage with a high debt-to-equity ratio of -13.32 in the TTM, indicating potential financial risk. The negative stockholders' equity suggests that liabilities exceed assets, which is concerning. Return on equity is positive at 1.14%, but this is due to negative equity, which distorts the metric.

Cash Flow

The cash flow statement shows a concerning decline in free cash flow growth of -398.69% in the TTM, highlighting cash management challenges. However, the free cash flow to net income ratio is positive at 1.05, indicating that the company is generating cash relative to its net losses. The operating cash flow to net income ratio is negative, reflecting ongoing operational cash flow issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2023	Dec 2023	Dec 2023
Income Statement
Total Revenue	266.14M	203.07M	163.91M	163.91M	163.91M	163.91M
Gross Profit	222.33M	166.24M	135.27M	135.27M	135.27M	135.27M
EBITDA	26.62M	-13.99M	-23.73M	-23.73M	-23.73M	-23.73M
Net Income	-15.64M	-54.84M	-62.26M	-62.26M	-62.26M	-62.26M
Balance Sheet
Total Assets	370.19M	323.06M	322.60M	322.60M	322.60M	322.60M
Cash, Cash Equivalents and Short-Term Investments	91.60M	71.62M	72.45M	72.45M	72.45M	72.45M
Total Debt	38.19M	271.45M	229.19M	229.19M	229.19M	229.19M
Total Liabilities	371.05M	352.68M	329.38M	329.38M	329.38M	329.38M
Stockholders Equity	-861.00K	-29.61M	-6.78M	-6.78M	-6.78M	-6.78M
Cash Flow
Free Cash Flow	19.82M	-37.85M	-49.29M	-49.29M	-49.29M	-49.29M
Operating Cash Flow	10.56M	-36.98M	-47.02M	-47.02M	-47.02M	-47.02M
Investing Cash Flow	9.65M	4.88M	-6.00M	-6.00M	-6.00M	-6.00M
Financing Cash Flow	12.05M	36.17M	-1.61M	-1.61M	-1.61M	-1.61M

Xeris Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Neutral. The current price of 9.08 is above the 20-day moving average (MA) of 7.89, above the 50-day MA of 8.26, and above the 200-day MA of 5.99, indicating a neutral trend. The MACD of -0.45 indicates Positive momentum. The RSI at 37.98 is Neutral, neither overbought nor oversold. The STOCH value of 42.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XERS.

Xeris Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	60 Neutral	$1.78B	47.30	15.02%	―	1128.17%	―
ZYME	58 Neutral	$2.06B	―	-18.46%	―	116.21%	43.93%
RCUS	57 Neutral	$3.16B	―	-68.13%	―	-8.75%	-8.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XERS	49 Neutral	$1.59B	―	―	―	42.05%	76.50%
SNDX	48 Neutral	$1.69B	―	-129.32%	―	597.19%	0.45%
RAPP	44 Neutral	$1.40B	―	-23.41%	―	―	―

Xeris Pharmaceuticals Corporate Events

Xeris Biopharma Reports Strong Q3 2025 Financial Results

Xeris Biopharma Holdings, Inc. is a rapidly expanding biopharmaceutical company dedicated to enhancing patient lives through the development and commercialization of innovative therapeutic products. The company operates in the healthcare sector, with a focus on treatments for conditions such as endogenous Cushing’s syndrome, severe hypoglycemia, and primary periodic paralysis.

Xeris Biopharma Reports Record Revenue Growth in Earnings Call

Xeris Biopharma’s recent earnings call painted a picture of robust financial health and strategic optimism. The company reported record revenue growth, driven by strong product performance, particularly from RECORLEV. Despite facing increased expenses and potential competitive pressures, Xeris remains confident in its strategic growth plans and financial milestones, suggesting a positive outlook.

Xeris Pharmaceuticals Reports Record Revenue and Growth

Xeris Pharmaceuticals’ recent earnings call painted a picture of robust financial health and promising growth prospects. The company reported a record-breaking quarter with significant revenue growth and increased demand for its key products, particularly Recorlev. Despite some challenges, such as increased expenses and a slight decline in gross margin, the overall sentiment was positive, with raised revenue guidance and a favorable adjusted EBITDA.